Chronic Lymphocytic Leukemia, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type, Small Lymphocytic Lymphoma
Conditions
Brief summary
retrospective and prospective multicenter observational clinical and biological data collection from all patients with newly diagnosed CLL, SLL or MBL. retrospective cohort: all cases with a diagnosis between January 1st 2010 and August 31th 2021. prospective cohort: all patients with a diagnosis between September 1st 2021 and September 1st 2025.
Detailed description
This is a retrospective and prospective multicenter observational study designed by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA). The study consists of clinical and biological data collection from all patients with newly diagnosed CLL, SLL or MBL (according to the WHO 2007 and 2018 diagnostic criteria). The retrospective part aims at including all cases followed at participating centers with a diagnosis between January 1st 2010 and August 31th 2021 (planned study initiation), while the prospective part will include all patients with a documented diagnosis of CLL, SLL or MBL between September 1st 2021 and September 1st 2025 by the first immunophenotypic/histological evaluation. The data is collected through electronic case report form accessible by the participating centers on a dedicated platform.
Interventions
None listed
Sponsors
Gruppo Italiano Malattie EMatologiche dell'Adulto
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years at diagnosis 2. One of the following diagnoses that meet the international diagnostic criteria (iwCLL2018 and WHO2017) 1. Chronic lymphocytic leukemia (CLL) 2. Small lymphocytic lymphoma (SLL) 3. CLL-like monoclonal B-cell lymphocytosis (MBL) 3. Retrospective cohort: CLL/SLL/MBL diagnosis between January 1st 2010 and August 31th 2021. 4. Prospective cohort: CLL/SLL/MBL diagnosis between September 1st 2021 and September 1st, 2025. 5. Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable)
Exclusion criteria
* \- -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Describe the diagnosis and management of CLL patients | at 1 year for the prospective cohort and at 4 years for the retrospective cohort | evaluation of CLL management in terms of time to first treatment |
Countries
Italy
Contacts
Primary ContactPaola Fazi
Backup ContactEnrico Crea
Outcome results
None listed